These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24403024)

  • 1. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
    Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Huber EM; Heinemeyer W; Groll M
    Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
    Carmony K; Lee W; Kim KB
    Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors.
    Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M
    J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate.
    Hu G; Lin G; Wang M; Dick L; Xu RM; Nathan C; Li H
    Mol Microbiol; 2006 Mar; 59(5):1417-28. PubMed ID: 16468986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
    Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
    Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Keto phenylamides as P1'-extended proteasome inhibitors.
    Voss C; Scholz C; Knorr S; Beck P; Stein ML; Zall A; Kuckelkorn U; Kloetzel PM; Groll M; Hamacher K; Schmidt B
    ChemMedChem; 2014 Nov; 9(11):2557-64. PubMed ID: 25087721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors.
    Cvek B
    Prog Mol Biol Transl Sci; 2012; 109():161-226. PubMed ID: 22727422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Based Optimization of Covalent Reversible Ketoamide Inhibitors Bridging the Unprimed to the Primed Site of the Proteasome β5 Subunit.
    Stubba D; Bensinger D; Steinbacher J; Proskurjakov L; Salcedo Gómez Á; Schmidt U; Roth S; Schmitz K; Schmidt B
    ChemMedChem; 2019 Dec; 14(23):2005-2022. PubMed ID: 31675179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome.
    Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S
    Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M; Berkers CR; Ploegh HL; Ovaa H
    Structure; 2006 Mar; 14(3):451-6. PubMed ID: 16531229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding.
    Kikuchi J; Shibayama N; Yamada S; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Sugiyama K; Ohki M; Park SY; Furukawa Y
    PLoS One; 2013; 8(4):e60649. PubMed ID: 23593271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.